thawed, transduced cells will be admixed with the thawed, non- 
transduced bone marrow cells and reinfused into the patient on Day 
7 of treatment (see Section 6.0). 
Hematologic colony numbers produced in methylcellulose by an 
aliquot of non-transduced and transduced marrow mononuclear cells 
will be measured in the presence and absence of G418. Confirmation 
of transduction in positively-identified G418 colonies will be 
obtained by PCR. The sites of viral integration in G418 selected CFU- 
GM's obtained from patients after ABMT may be examined to assess 
the degree of clonability. Viral integration sites in relapsed tumor 
will also be studied if adequate tissue is obtained. Southern blot 
and PCR analysis will be used to conduct these studies. 
8.0 Pharmaceutical Information 
8.1 Ifosfamide is commercially available and is supplied as a 
lyophilized powder in T and 3 gram vials. Reconstitution with 
20 ml sterile water for injection (SWF) for the 1 grams vial 
and 60 ml SWFI for the 3 gram vial yields a 50 mg/ml solution 
which is stable for at least 7 days at 4 degrees C. Ifosfamide 
is compatible with D5W or NS and mixtures of ifosfamide and 
MESNA in D5W shew less than a 5% degradation of MESNA and 
ifosfamide after 24 hours. 
8.2 MESNA is commercially available and is supplied as a 
lOOma/ml solution in single dose ampules in 2. 4 and 10 ml 
sizes. MESNA is compatible with D5W or NS for further 
dilution. 
8.3 CBDCA (carboplatin) is commercially available and is supplied 
as a sterile, freeze-dried, white powder in 20 ml vials 
containing 50, 150 or 450 mgs of drug. Reconstitution of 150 
mg mixed with 9.8 ml SWFI yields a 15 mg/ml solution. Also, 
reconstitution may be done by adding 5, 15, or 45 ml of D5W, 
NS or SWFI to the 50, 150 or 450 mg vials, respectively to 
yield 10 mg/ml concentration. Normal saline is not 
recommended as the final dilution vehicle due to accelerated 
Recombinant DNA Research, Volume 16 
[113] 
